About the Registry

Who is eligible for the Registry?

All pregnant women ages 18-45 who are currently treated with one or more of the following atypical antipsychotics:

Abilify (aripiprazole)
Clozaril (clozapine)
Geodon (ziprasidone)
Invega (paliperidone)
Risperdal (risperidone)
Seroquel (quetiapine)
Zyprexa (olanzapine)
Saphris (asenapine)

Click here to view the IRB-approved research advertisement.

For Patients: What does participation in the Registry involve?

Participation in the Registry involves three phone interviews:

The baseline interview is conducted as soon as possible after you learn that you are pregnant to obtain information about your psychiatric and physical health, pregnancy, etc. (approximately 20 minutes)
Registry staff will call you when you are 7 months pregnant to follow up on the status of your health and pregnancy (approximately 10 minutes)
Registry staff will call you for your final interview after your baby is born (approximately 10 minutes).

We will also request copies of medical records for you and your child to obtain information about maternal and neonatal outcomes.

For Health Care Providers: How to refer a patient to the Registry

Please have eligible patients (pregnant, taking 1 or more atypical antipsychotics, age 18-45) call our toll-free number: 1-866-961-2388. Please do not hesitate to call us if you have questions about the Registry.

Registry Funding Information

We have approached the five primary U.S. manufacturers of atypical antipsychotics regarding funding of the National Pregnancy Registry for Atypical Antipsychotics. We are currently funded by Bristol Myers-Squibb (BMS), Ortho-McNeil Janssen, AstraZeneca, and Pfizer.

Click here to return to the main Registry page.